GlassScriptPhysician profile
Jennifer Evans Watson
NPI 1891813218
$2,357.99
in general payments reported to CMS, 2019-2025
31 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $79.57 · 2021: $125 · 2022: $395 · 2023: $688 · 2024: $368 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $462.33 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $387.75 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Sumitomo Pharma America, INC. | $199.51 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $164.09 | 2022-2025 | |
| Baxter Healthcare | $124.88 | 2021 | |
| Exeltis, USA INC. | $93.83 | 2019-2024 | Slynd |
| Organon LLC | $79.65 | 2022-2025 | Jada System |
| Pfizer INC. | $76.68 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $56.33 | 2019-2024 | Gardasil 9, Gardasil |
| Ascend Therapeutics US, LLC | $56.20 | 2022-2023 | |
| Dysis Medical, INC. | $55.10 | 2020-2023 | Dysis View, Dysis V3 Digital Coploscope, Dysis Ultra 2.0 |
| Evofem Biosciences, INC. | $53.31 | 2022 | |
| Myovant Sciences INC. | $52.84 | 2022 | |
| Sage Therapeutics, LLC | $49.04 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $42.32 | 2019-2023 | Mara Console |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $41.54 | 2022 | |
| Meditrina | $37.51 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.68 | 2019-2023 | |
| Vertical Pharmaceuticals, LLC | $34.64 | 2019 | |
| Scynexis, INC. | $30.51 | 2022 | |
| Olympus America INC. | $26.02 | 2024 | Olympus |
| Supernus Pharmaceuticals, INC. | $25.59 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $25.44 | 2019-2022 | |
| Millicent US INC | $23.14 | 2025 | Femlyv |
| Channel Medsystems, INC. | $22.43 | 2023 | |
| Allergan, INC. | $21.80 | 2019 | |
| Novo Nordisk INC | $19.73 | 2023 | Wegovy |
| Hologic Sales and Service, LLC | $17.81 | 2023 | Myosure Tissue Removal Device, Acessa Provu System, Coolseal Generator |
| Medtronic, INC. | $16.06 | 2025 | Truclear |
| Agile Therapeutics, INC. | $12.71 | 2023 | Twirla |
| Amag Pharmaceuticals, INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.